Faculty

The DDI Workshop Series was founded in 2010 as a private initiative of four experts in the field from academia and industry, intrigued by the notion that the field of drug-drug interactions (DDIs) is getting increasingly important and complex.

The Faculty members do have different academic and professional backgrounds, thereby complementing each other in their scientific and practical DDI experiences, perspectives and approaches.

For details, please refer to the respective CVs.

Hartmut Derendorf, PhD, FCP

Hartmut Derendorf, PhD, FCP
Hartmut Derendorf, PhD, FCP

Hartmut Derendorf is Distinguished Professor Emeritus in the Department of Pharmaceutics at the University of Florida College of Pharmacy in Gainesville. He received his B.S. (1976) and Ph.D. (1979, summa cum laude) in Pharmacy from the University of Münster, Germany and then joined the University of Florida, first as a Postdoctoral Fellow (1981/82) and later (1983) as a faculty member. He has been teaching Biopharmaceutics, Pharmacokinetics and Clinical Pharmacokinetics. He was awarded numerous teaching awards such as the UF Teaching Improvement Award, HHMI Distinguished Mentorship Award, UF Research Foundation Professorship, CVS Pharmacy Endowed Professorship, International Educator of the Year Award and UF Doctoral Advisor/Mentoring Award (2009 and 2018). He has supervised over 50 Ph.D. students.

Prof. Derendorf has published over 500 scientific publications (h-index Google Scholar 72, Scopus 58) and given over 1000 presentations at national or international meetings. He has published ten textbooks in English and German. He is Editor or Associate Editor of the Journal of Clinical Pharmacology, International Journal of Clinical Pharmacology & Therapeutics, International Journal of Antimicrobial Agents and Die Pharmazie, and serves on the Editorial Board of several other Journals. His research interests include the pharmacokinetics and pharmacodynamics of corticosteroids, analgesics, antibiotics as well as drug interactions.

Prof. Derendorf has served as President of ACCP (American College of Clinical Pharmacology) in 2006/08 and President of ISAP (International Society of Antiinfective Pharmacology) in 2004/06. He won the McKeen-Cattell Award for the best publication in J. Clin. Pharmacology (1994) and the Faculty Award of the University of Utrecht (2005). In 2003, he was awarded the Nathaniel T. Kwit Distinguished Service Award of ACCP and the Research Achievement Award in Clinical Science of the American Association of Pharmaceutical Sciences (AAPS). He is a Fellow of AAPS and ACCP as well as a former review panel member of the NASA Human Research Program. In 2010, he was awarded the Volwiler Award of the American Association of Colleges of Pharmacy (AACP) as well as the ACCP Distinguished Investigator Award, the highest research awards of both organizations. In 2013, he was awarded the First Leadership Award of the International Society of Pharmacometrics (ISOP). In 2015 he received the Merit Medal of the Westphalian Chamber of Pharmacy as well as the ACCP Mentorship Award. In 2018 he received the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Mentor Award. He also served as the 18th University of Florida Distinguished Alumni Professor.

Robert Hermann, MD, FCP

Robert Hermann, MD, FCP
Robert Hermann, MD, FCP

Robert underwent medical training at the Johann-Wolfgang-Goethe University in Frankfurt and obtained his M.D. (1982) and Ph.D. (1984). Thereafter, he specialised and earned accreditations as a board certified Anaesthesiologist and Clinical Pharmacologist. After 8 years in clinical medicine, he joined the pharmaceutical industry in 1990 and assumed over the years various expert and managing functions of increasing responsibility in Clinical Pharmacology, Translational- and Exploratory-Medicine, including VP and CMO roles. He and his teams contributed significantly to the clinical development and international regulatory approval of several products, including three “first-in-class” NMEs.

The scientific activities of Robert in the field of early clinical drug development are reflected by contributions to more than 100 publications, reviews, and book articles, many of them highly cited (> 4,000 citations, H-Index = 32, i10-Index = 63). He serves also as acting reviewer for various international Clinical Pharmacology and Clinical Pharmacokinetic Peer Journals.

Robert is Fellow of the American College of Clinical Pharmacology (FCP), founder member of the Association for Applied Human Pharmacology (AGAH), and member of the German Society for Pharmaceutical Medicine (DGPharMed), the European Respiratory Society (ERS), and the International Society for Aerosols in Medicine (ISAM).

He also served as a member and Chair of the Board of Trustees of the Fraunhofer Institute for Toxicology & Experimental Medicine (ITEM), Hannover, Germany, for more than a decade. In this capacity, Robert mentored the foundation of a dedicated respiratory experimental medicine group at ITEM, as well as the establishment of an environmental exposure unit for the conduct of well standardized allergen challenge studies (e.g. pollen studies in allergic rhinitis, etc.).

Robert is also co-founder and Faculty Member of the International Marbach Castle Drug-Drug Interaction Workshop series (established in 2010), which is dedicated to improve and disseminate the scientific knowledge about regulatory requirements and current scientific aspects on the preclinical and clinical investigation of drug-drug interactions.

Since 2008, Robert runs his own business and serves as an independent consultant to the pharmaceutical and biotech industry in the field of early clinical development as owner and managing director of cr.appliance (www.cr-appliance.com).

Amin Rostami-Hodjegan, PhD, FCP, FAAPS, FJSSX

Amin Rostami-Hodjegan, PhD, FCP, FAAPS, FJSSX
Amin Rostami-Hodjegan, PhD, FCP, FAAPS, FJSSX

Amin is Director of the Centre for Applied Pharmacokinetic Research (CAPKR) at the University of Manchester. In 2007, whilst working at the University of Sheffield, he was the first full Professor appointed with the title of Systems Pharmacology. Professor Rostami has authored/co-authored over 250 highly cited articles (>14,000 citations, H-Factor = 62). In 2017, he was listed by ISI as one of the world’s most highly cited researchers (under ‘Pharmacology & Toxicology’). He was a founding editor of Pharmacometrics and System Pharmacology and serves on the Editorial Boards of several other journals (e.g. BDD, CDM, CPDD, DMPK). Professor Rostami is renowned for his contribution to translational modelling (e.g. PBPK) and has been an invited speaker at over 200 international and national meetings, in addition to leading numerous workshops in the area of IVIVE- PBPK linked models.

Professor Rostami has an active program of training PhD students involving proteomics, PBPK, clinical PKPD and precision dosing. Graduates from his team hold positions in the pharmaceutical industry or academia.

As a co-founder of Simcyp Limited (a University of Sheffield spin-off acquired by Certara), Amin joined Certara in 2012. Certara is the largest company focused on modelling and Simulation in the pharmaceutical industry. As the Senior Vice President of Research & Development and Chief Scientific Officer at Certara, he ensures that the latest scientific advances in the field of biosimulation are incorporated into all of the drug development efforts by various pharmaceutical companies.

Oliver von Richter, PhD, FCP

Oliver is co-founder of the International Marbach Castle Drug-Drug Interaction Workshop series that was established in 2010. He served as Faculty Member from 2010 – 2018